Mereo BioPharma Group plc (AIM:MPH)

Mereo BioPharma Group Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.5	-	10	-	49.37
Cost of Revenue	0.13	-	2.57	-1.15	24.25
Gross Profit	0.37	-	7.43	1.15	25.13
Selling, General & Admin	23.01	26.43	18.42	26.11	21.57
Research & Development	15.92	19.28	16.14	27.74	31.9
Operating Expenses	38.92	45.72	34.56	53.84	53.47
Operating Income	-38.56	-45.72	-27.14	-52.7	-28.35
Interest Expense	-0.26	-1.37	-2.88	-4.18	-5.11
Interest & Investment Income	2.17	3.04	2.13	0.84	0
Currency Exchange Gain (Loss)	-6.34	1.21	-2.35	2.72	-1.29
Other Non Operating Income (Expenses)	0.81	-0.42	0.24	10.37	53.88
EBT Excluding Unusual Items	-42.18	-43.25	-30	-42.94	19.13
Merger & Restructuring Charges	0.3	-	-	-	-
Gain (Loss) on Sale of Assets	-	-	-	-	0.15
Pretax Income	-41.88	-43.25	-30	-42.94	19.28
Income Tax Expense	-	-	-0.53	-0.72	2.05
Net Income	-41.88	-43.25	-29.47	-42.22	17.23
Net Income to Common	-41.88	-43.25	-29.47	-42.22	17.23
Shares Outstanding (Basic)	159	148	132	121	106
Shares Outstanding (Diluted)	159	148	132	121	111
Shares Change (YoY)	7.77%	12.16%	9.33%	8.63%	63.82%
EPS (Basic)	-0.26	-0.29	-0.22	-0.35	0.16
EPS (Diluted)	-0.26	-0.29	-0.22	-0.35	-0.31
Free Cash Flow	-30.99	-32.83	-21.13	-48.83	-7.82
Free Cash Flow Per Share	-0.19	-0.22	-0.16	-0.41	-0.07
Gross Margin	73.40%	-	74.26%	-	50.89%
Operating Margin	-7711.40%	-	-271.36%	-	-57.42%
Profit Margin	-8375.60%	-	-294.66%	-	34.90%
Free Cash Flow Margin	-6198.20%	-	-211.32%	-	-15.83%
EBITDA	-37.94	-45.13	-26.57	-52.52	-28.25
EBITDA Margin	-	-	-265.70%	-	-57.22%
D&A For EBITDA	0.62	0.58	0.57	0.18	0.1
EBIT	-38.56	-45.72	-27.14	-52.7	-28.35
EBIT Margin	-	-	-271.36%	-	-57.42%
Effective Tax Rate	-	-	-	-	10.64%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.